- Partnership agreements will further diversify Lotus revenue base and create partnerships with leading global pharma companies
Lotus Pharmaceutical Co., Ltd. (“Lotus” or “the Company”, Taiwan TWSE ticker: 1795) today announced that it has made 10 new strategic partnership agreements in 2020 with some of the world’s leading pharmaceutical companies. The regions covered by these partnerships include the European Union, Middle East and North Africa (MENA), South Africa, Israel, Canada, Brazil and Columbia.
otus will be responsible for the development, regulatory affairs and manufacturing of the products for its partners that include Lenalidomide, Sunitinib, Enzalutamide. Recent partnership agreements have also been made for products still under development coming from Lotus’ leading oncology portfolio.
Petar Vazharov, Chief Executive Officer of Lotus, commented: